NasdaqGS - Nasdaq Real Time Price USD

Kiniksa Pharmaceuticals International, plc (KNSA)

Compare

19.93

-0.37

(-1.82%)

At close: January 10 at 4:00:01 PM EST

19.93

0.00

(0.00%)

After hours: January 10 at 5:33:45 PM EST

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours

GlobeNewswire 4 days ago

KNSA
-1.82%
Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and an anticipated annual earnings growth of 15%. In this dynamic environment, identifying high-growth tech stocks involves assessing their potential to capitalize on technological advancements and market trends while aligning with robust growth forecasts.

Simply Wall St. 21 days ago

VNDA

ATYR

KNSA
-1.82%
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 4

GlobeNewswire last month

KNSA
-1.82%
Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?

We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a look at where Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) stands against other top performing European stocks. As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer […]

Insider Monkey last month

KNSA
-1.82%
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:00 p.m. Greenwich Mean Time (7:00 a.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’

GlobeNewswire last month

KNSA
-1.82%
Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

It's been a mediocre week for Kiniksa Pharmaceuticals International, plc ( NASDAQ:KNSA ) shareholders, with the stock...

Simply Wall St. 2 months ago

KNSA
-1.82%
Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations

Kiniksa Pharmaceuticals International ( NASDAQ:KNSA ) Third Quarter 2024 Results Key Financial Results Revenue...

Simply Wall St. 2 months ago

KNSA
-1.82%
Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call

Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call

Thomson Reuters StreetEvents 2 months ago

KNSA
-1.82%
Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ...

Kiniksa Pharmaceuticals International PLC (KNSA) reports a 73% year-over-year revenue increase, raises full-year sales guidance, and continues to expand its prescriber base.

GuruFocus.com 2 months ago

KNSA
-1.82%
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -1,700% and 1.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

KNSA
-1.82%
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $410 - $420 million –– Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY® Award-winning singer-songwriter, Carly Pearce –– Kiniksa expects to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8

GlobeNewswire 2 months ago

KNSA
-1.82%
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

– National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care – LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced a partnership with GRAMMY Award-winning singer-songwriter, Carly Pearce, as part of its L

GlobeNewswire 2 months ago

KNSA
-1.82%
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may regist

GlobeNewswire 2 months ago

KNSA
-1.82%
High Growth Tech Stocks To Watch In October 2024

The United States market has shown robust performance recently, climbing 1.5% in the last 7 days and up 33% over the past year, with earnings forecasted to grow by 16% annually. In this environment, a good high-growth tech stock typically demonstrates strong revenue growth potential and innovative capabilities that align with these optimistic market trends.

Simply Wall St. 2 months ago

OKTA

RNG

KNSA
-1.82%
Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet

The consensus price target hints at a 42.3% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 3 months ago

KNSA
-1.82%
Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals

Transaction Overview On October 4, 2024, Baker Bros. Advisors LP, a prominent investment firm specializing in the healthcare sector, added significantly to its holdings in Kiniksa Pharmaceuticals International PLC (NASDAQ:KNSA). This move not only reflects the firm's continued confidence in Kiniksa but also impacts its portfolio with a 0.11% increase in stake. About Baker Bros. Advisors LP Established in 2000 by Julian and Felix Baker, Baker Bros. Advisors LP has carved a niche in the investment world with its focus on life sciences companies.

GuruFocus.com 3 months ago

KNSA
-1.82%
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease – Hear from Henrik about how he took control of his life with recurrent pericarditis and how you can still live a balanced life with the right knowledge of RP and a treatment plan. Dr. Antonio Abbate, an RP expert, also discusses the nature of the disease and how you can own your path forward with RP. LONDON, Oct. 01, 2

GlobeNewswire 3 months ago

KNSA
-1.82%
Top High Growth Tech Stocks To Watch In September 2024

Over the last 7 days, the market has risen 4.2%, driven by gains of 7.4% in the Information Technology sector. The market is up 24% over the last 12 months, with earnings forecast to grow by 15% annually. In such a dynamic environment, identifying high growth tech stocks that align with these trends can be crucial for investors looking to capitalize on this momentum.

Simply Wall St. 3 months ago

KNSA
-1.82%
ADEA

TDC
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximate

GlobeNewswire 4 months ago

KNSA
-1.82%
Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade

The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 5 months ago

KNSA
-1.82%

Performance Overview

Return	KNSA	S&P 500
YTD	+1.68%	-1.35%
1-Year	+6.01%	+22.51%
3-Year	+81.84%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Exploring Three High Growth Tech Stocks In The United States

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations

Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call

Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

High Growth Tech Stocks To Watch In October 2024

Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet

Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals

NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

Top High Growth Tech Stocks To Watch In September 2024

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade

Performance Overview